Kolorektale Lebermetastasen: Aktueller Stand der multimodalen Therapie

 

 Buy Article Permissions and Reprints

Zusammenfassung

Die chirurgische Resektion stellt nach wie vor den einzigen kurativen Therapieansatz des hepatisch metastasierten kolorektalen Karzinoms dar und führt zu einer signifikanten Lebensverlängerung der Patienten. Sowohl der Anteil an Pa­tienten, die einer kurativen Resektion zugeführt werden können, als auch das Überleben nach Leber­resektion kann durch moderne multimodale Therapiekonzepte erhöht werden. Dazu haben Fortschritte der chemotherapeutischen Vor- und Nachbehandlung, aber auch der Chirurgie, der interventionellen Radiologie und nicht zuletzt der individualisierten Chemotherapie beigetragen. Durch die Vielzahl der Neuerungen lässt sich bisher noch nicht für alle Untergruppen der ins­gesamt inhomogenen Gruppe von Patienten mit ­hepatisch metastasiertem kolorektalen Karzinom ein einheitlicher Behandlungsalgorithmus aufstellen. In der folgenden Übersichtsarbeit werden der ­aktuelle Stand der multimodalen Therapie und die momentan noch offenen Fragen wieder­gegeben. 

Abstract

Surgical resection is the only chance of cure for patients with colorectal liver metastases und significantly improves patient survival. The per­centage of patients who can undergo curative resection as well as the survival after liver resection can be increased by using modern multimodal treatment algorithms. This has been achieved by not only innovations in pre- and postoperative chemotherapy but also by new surgical and interventional techniques and last but not least by individualisation of chemotherapeutic regimens. Due to the high number of new treatment modalities, a generally accepted treatment algorithm cannot be provided so far for all subgroups of the inhomogeneous group of patients with colorectal liver metastases. In the present review the current status of multimodal therapy is outlined and the pending questions mentioned. 

Literatur

• 1 Kopetz S, Chang G J, Overman M J et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.  J Clin Oncol. 2009;  27 3677-3683
  CrossrefPubMedGoogle Scholar
• 2 Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history.  Br J Surg. 1990;  77 1241-1246
  CrossrefPubMedGoogle Scholar
• 3 Neumann U P, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma.  Dtsch Arztebl Int. 2010;  107 335-342
  PubMedGoogle Scholar
• 4 Stübs P, Habermann P, Wex C et al. Palliative Chemotherapie beim kolo­rektalen Karzinom – Stand, Wertigkeit, Tendenzen.  Zentralbl Chir. 2010;  135 535-540
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Folprecht G, Gruenberger T, Bechstein W O et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.  Lancet Oncol. 2010;  11 38-47
  CrossrefPubMedGoogle Scholar
• 6 Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of un­resectable colorectal liver metastases: correlation between tumour response and resection rates.  Ann Oncol. 2005;  8 1311-1319
  PubMedGoogle Scholar
• 7 Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluoro­uracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.  J Clin Oncol. 2007;  25 1670-1676
  CrossrefPubMedGoogle Scholar
• 8 Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially un­resectable metastatic colorectal cancer patients treated with 5-fluoro­uracil / leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.  Ann Surg. 2009;  249 420-425
  CrossrefPubMedGoogle Scholar
• 9 Saltz L B, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.  J Clin Oncol. 2008;  26 2013-2019
  CrossrefPubMedGoogle Scholar
• 10 Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line ­bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.  Ann Oncol. 2009;  20 1842-1847
  CrossrefPubMedGoogle Scholar
• 11 Van Cutsem E, Köhne C H, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.  N Engl J Med. 2009;  360 1408-1417
  CrossrefPubMedGoogle Scholar
• 12 Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2009;  27 663-671
  CrossrefPubMedGoogle Scholar
• 13 Garufi C, Torsello A, Tumolo S et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.  Br J Cancer. 2010;  103 1542-1547
  CrossrefPubMedGoogle Scholar
• 14 Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.  J Clin Oncol. 2009;  27 663-671
  CrossrefPubMedGoogle Scholar
• 15 Ricke J, Hildebrandt B, Miersch A et al. Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events.  J Vasc Interv Radiol. 2004;  15 825-833
  CrossrefPubMedGoogle Scholar
• 16 Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009 8 CD007823
  Google Scholar
• 17 Elias D, Goere D, Boige V et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin.  Ann Surg Oncol. 2007;  14 3188-3194
  CrossrefPubMedGoogle Scholar
• 18 Kemeny N E, Melendez F D, Capanu M et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.  J Clin Oncol. 2009;  27 3465-3471
  CrossrefPubMedGoogle Scholar
• 19 Boige V, Malka D, Elias D et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.  Ann Surg Oncol. 2008;  15 219-226
  CrossrefPubMedGoogle Scholar
• 20 Vauthey J N, Pawlik T M, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.  J Clin Oncol. 2006;  24 2065-2072
  Google Scholar
• 21 Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.  J Clin Oncol. 2006;  24 4983-4990
  CrossrefPubMedGoogle Scholar
• 22 Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.  Ann Oncol. 2004;  15 460-466
  Google Scholar
• 23 Rubbia-Brandt L, Lauwers G Y, Wang H et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.  Histopathology. 2010;  56 430-439
  CrossrefPubMedGoogle Scholar
• 24 Hubert C, Sempoux C, Horsmans Y et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?.  Liver Int. 2007;  27 938-943
  CrossrefPubMedGoogle Scholar
• 25 Wicherts D A, de Haas R J, Sebagh M et al. Regenerative Nodular Hyperplasia of the Liver Related to Chemotherapy: Impact on Outcome of Liver Surgery for Colorectal Metastases.  Ann Surg Oncol. 2010;  [Epub ahead of print]
  PubMedGoogle Scholar
• 26 Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup Trial 40983): a randomised controlled trial.  Lancet. 2008;  371 1007-1016
  CrossrefPubMedGoogle Scholar
• 27 Peppercorn P D, Reznek R H, Wilson P et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluoro­uracil-based therapy for advanced colorectal cancer.  Br J Cancer. 1998;  77 2008-2011
  CrossrefPubMedGoogle Scholar
• 28 McCormack L, Petrowsky H, Jochum W et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: A ­matched case-control study.  Ann Surg. 2007;  245 923-930
  CrossrefPubMedGoogle Scholar
• 29 Brouquet A, Benoist S, Julie C et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases.  Surgery. 2009;  145 362-371
  CrossrefPubMedGoogle Scholar
• 30 Vauthey J N, Pawlik T M, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.  J Clin Oncol. 2006;  24 2065-2072
  Google Scholar
• 31 Mahfud M, Breitenstein S, El-Badry A M et al. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.  World J Surg. 2010;  34 92-100
  CrossrefPubMedGoogle Scholar
• 32 Klinger M, Eipeldauer S, Hacker S et al. Bevacizumab protects against ­sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX / FOLFOX therapy of colorectal cancer liver ­metastases.  Eur J Surg Oncol. 2009;  35 515-520
  CrossrefPubMedGoogle Scholar
• 33 Pessaux P, Panaro F, Casnedi S et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.  Eur J Surg Oncol. 2010;  36 575-582
  CrossrefPubMedGoogle Scholar
• 34 Aussilhou B, Dokmak S, Faivre S et al. Preoperative liver hypertrophy ­induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.  Ann Surg Oncol. 2009;  16 1553-1559
  CrossrefPubMedGoogle Scholar
• 35 Kishi Y, Zorzi D, Contreras C M et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.  Ann Surg Oncol. 2010;  17 2870-2876
  CrossrefPubMedGoogle Scholar
• 36 Glazer E S, Beaty K, Abdalla E K et al. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases.  Arch Surg. 2010;  145 340-345
  CrossrefPubMedGoogle Scholar
• 37 Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.  J Clin Oncol. 2008;  26 1830-1835
  CrossrefPubMedGoogle Scholar
• 38 Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.  Ann Surg. 2006;  243 1-7
  Google Scholar
• 39 Lock J F, Westphal T, Malinowski M et al. Impact of neoadjuvant chemotherapy in colorectal liver metastases on liver function before hepatectomy (abstr.).  HPB. 2010;  12 352
  PubMedGoogle Scholar
• 40 Overman M J, Maru D M, Charnsangavej C et al. Oxaliplatin-mediated ­increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.  J Clin Oncol. 2010;  28 2549-2555
  CrossrefPubMedGoogle Scholar
• 41 Stockmann M, Lock J F, Malinowski M et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery.  HPB (Oxford). 2010;  12 139-146
  CrossrefPubMedGoogle Scholar
• 42 Wicherts D A, de Haas R J, Andreani P et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases.  Br J Surg. 2010;  97 240-250
  CrossrefPubMedGoogle Scholar
• 43 Kokudo N, Tada K, Seki M et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization.  Hepatology. 2001;  34 267-272
  Google Scholar
• 44 Elias D, De Baere T, Roche A et al. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma.  Br J Surg. 1999;  86 784-788
  Google Scholar
• 45 Goéré D, Farges O, Leporrier J et al. Chemotherapy does not impair ­hypertrophy of the left liver after right portal vein obstruction.  J Gastrointest Surg. 2006;  10 365-370
  CrossrefPubMedGoogle Scholar
• 46 Beal I K, Anthony S, Papadopoulou A et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy.  Br J Radiol. 2006;  79 473-478
  CrossrefPubMedGoogle Scholar
• 47 Covey A M, Brown K T, Jarnagin W R et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases.  Ann Surg. 2008;  247 451-455
  CrossrefPubMedGoogle Scholar
• 48 Wicherts D A, Miller R, de Haas R J et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases.  Ann Surg. 2008;  248 994-1000
  CrossrefPubMedGoogle Scholar
• 49 Jaeck D, Oussoultzoglou E, Rosso E et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative ­resection for initially unresectable multiple and bilobar colorectal liver metastases.  Ann Surg. 2004;  240 1037-1049
  CrossrefPubMedGoogle Scholar
• 50 Petrowsky H, Gonen M, Jarnagin W et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: A bi-institutional analysis.  Ann Surg. 2002;  235 863-871
  CrossrefPubMedGoogle Scholar
• 51 Hopt U T, Drognitz O, Neeff H. Zeitlicher Ablauf von Leber- und Darm­resektion bei Patienten mit kolorektalem Karzinom und synchronen Lebermetastasen.  Zentralbl Chir. 2009;  134 425-429
  Article in Thieme ConnectPubMedGoogle Scholar
• 52 Mentha G, Majno P E, Andres A et al. Neoadjuvant chemotherapy and ­resection of advanced synchronous liver metastases before treatment of the colorectal primary.  Br J Surg. 2006;  93 872-878
  CrossrefPubMedGoogle Scholar
• 53 Brouquet A, Mortenson M M, Vauthey J N et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?.  J Am Coll Surg. 2010;  210 934-941
  CrossrefPubMedGoogle Scholar
• 54 de Haas R J, Wicherts D A, Flores E et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?.  Ann Surg. 2008;  248 626-636
  PubMedGoogle Scholar
• 55 Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?.  Ann Surg. 2004;  240 1052-1061
  CrossrefPubMedGoogle Scholar
• 56 Allen P J, Kemeny N, Jarnagin W et al. Importance of response to neo­adjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases.  J Gastrointest Surg. 2003;  7 109-115
  CrossrefPubMedGoogle Scholar
• 57 Neumann U P, Thelen A, Röcken C et al. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.  Surgery. 2009;  146 52-59
  CrossrefPubMedGoogle Scholar
• 58 Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.  Ann Oncol. 2009;  20 985-992
  CrossrefPubMedGoogle Scholar
• 59 Schmiegel W, Reinacher-Schick A, Arnold D et al. S3-Leitlinie „Kolo­rektales Karzinom“ – Aktualisierung 2008.  Z Gastroenterol. 2008;  46 799-840
  Article in Thieme ConnectPubMedGoogle Scholar
• 60 Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?.  J Clin Oncol. 2006;  24 3939-3935
  CrossrefPubMedGoogle Scholar
• 61 Adam R, Bhangui P, Poston G et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?.  Ann Surg. 2010;  252 774-787
  CrossrefPubMedGoogle Scholar
• 62 Mitry E, Fields A L, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.  J Clin Oncol. 2008;  26 4906-4911
  CrossrefPubMedGoogle Scholar
• 63 Parks R, Gonen M, Kemeny N et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.  J Am Coll Surg. 2007;  204 753-761
  CrossrefPubMedGoogle Scholar
• 64 Ychou M, Hohenberger W, Thezenas S et al. A randomized phase III study comparing adjuvant 5-fluorouracil / folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.  Ann Oncol. 2009;  20 1964-1970
  CrossrefPubMedGoogle Scholar
• 65 Helmberger T. Interventionelle Verfahren bei Lebermetastasen.  Chirurg. 2010;  81 542-550
  CrossrefPubMedGoogle Scholar
• 66 Elias D, Baton O, Sideris L et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases.  J Surg Oncol. 2005;  90 36-42
  Google Scholar
• 67 Ruers T, van Coevorden F, Pierie J et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Interim results of a randomised phase II study of the EORTCNCRI CCSG-ALM Intergroup 40004 (CLOCC). 2008 Orlando, FL; ASCO Gastrointestinal Cancers Symposium, abstr 4012
  Google Scholar
• 68 Ricke J, Mohnike K, Pech M et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy.  Int J Radiat Oncol Biol Phys. 2010;  78 479-485
  CrossrefPubMedGoogle Scholar

Dr. D. Seehofer

Charité – Universitätsmedizin Berlin · Campus Virchow Klinikum · Klinik für Allgemein-, Viszeral- und Transplantationschirurgie

13353 Berlin

Deutschland

Phone: 0 30 / 4 50 55 20 01

Fax: 0 30 / 4 50 55 29 00

Email: daniel.seehofer@charite.de